RMTI News and Press, Rockwell Medical Inc. From 02/08/24

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth ...

2024-01-08 11:49:55 ET More on Rockwell Medical Returning To Rockwell Medical: Buy At 65% Of Revenue Rockwell Medical Q3 2023 Earnings Call Transcript Rockwell Medical GAAP EPS of -$0.07, revenue of $23.8M Rockwell Medical Q3 2023 Earnings Preview See...

Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enhances the Company's cash balance Rockwell Medical provides preliminary projected fourth quarter and full-year 2023 financial results Rockwell Medic...

2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...

2023-11-30 01:42:46 ET Summary Rockwell Medical is arguably the strongest player in the hemodialysis market and a top 5 healthcare supplier per Seeking Alpha Quant. The Company still addresses a critical medical condition and has a large global market that I don't believe is near ...

2023-11-14 09:58:03 ET Rockwell Medical, Inc. (RMTI) Q3 2023 Earnings Conference Call November 14, 2023 08:00 AM ET Company Participants Heather Hunter - SVP & Chief Corporate Affairs Officer Mark Strobeck - President & CEO Jesse Neri - SVP, Finance ...

2023-11-14 06:10:10 ET More on Rockwell Medical Rockwell Medical: A Cautiously Optimistic Path Forward (Rating Upgrade) Rockwell Medical Q3 2023 Earnings Preview Rockwell Medical enters into product purchase deal with Centers for Dialysis Care Seeking Alpha&#...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. Gross profit for the third quarter of 2023 increased 183% over the same period in 2022. Gross marg...

Rockwell Medical Inc. (RMTI) is expected to report $-0.12 for Q3 2023